Group 1 - The core stock price of Kangchen Pharmaceutical (01681.HK) reached 9.760 HKD, marking a 4.27% increase from the previous trading day, with an intraday high of 9.900 HKD, the highest in nearly a year [1] - The net capital inflow for the day was 12.65 million HKD, with a total inflow of 24.97 million HKD and outflow of 12.32 million HKD [1] - Kangchen Pharmaceutical Group Limited, founded in 1997 and listed in Hong Kong in 2013, operates under well-known brands such as Kangchen and Yulin, with business spanning over 30 countries and regions [1] Group 2 - The company has established four production bases in Guangdong Guangzhou, Inner Mongolia Tongliao, Guangxi Yulin, and Xinjiang Horgos, employing over 3,000 people [2] - Kangchen Pharmaceutical focuses on nephrology as its flagship area, with a diverse product portfolio of 138 varieties, including 62 traditional Chinese medicine and 76 Western medicine products, with 33 varieties listed in the national essential drug list and 67 in the national medical insurance catalog [2] - The company has invested in a "Kidney Disease Drug Research Center" and collaborates with prestigious universities for research and development, aiming to become a leading pharmaceutical enterprise across multiple specialties [2]
康臣药业盘中最高价触及9.900港元，创近一年新高